Follow
Cyrus Harmon
Cyrus Harmon
Olema Pharmaceuticals, Inc.
Verified email at olema.com
Title
Cited by
Cited by
Year
Initial sequencing and analysis of the human genome
US DOE Joint Genome Institute: Hawkins Trevor 4 Branscomb Elbert 4 Predki ...
nature 409 (6822), 860-921, 2001
301052001
A 1.1-Mb transcript map of the hereditary hemochromatosis locus
DA Ruddy, GS Kronmal, VK Lee, GA Mintier, L Quintana, R Domingo, ...
Genome research 7 (5), 441-456, 1997
1121997
Specific stereochemistry of OP-1074 disrupts estrogen receptor alpha helix 12 and confers pure antiestrogenic activity
SW Fanning, L Hodges-Gallagher, DC Myles, R Sun, CE Fowler, IN Plant, ...
Nature communications 9 (1), 2368, 2018
452018
Genoviz Software Development Kit: Java tool kit for building genomics visualization applications
GA Helt, JW Nicol, E Erwin, E Blossom, SG Blanchard, SA Chervitz, ...
BMC bioinformatics 10, 1-13, 2009
352009
System, method, and computer program product for the representation of biological sequence data
G Helt, C Harmon
US Patent App. 10/423,530, 2004
232004
Benzopyran compounds, compositions and uses thereof
PJ Kushner, DC Myles, CL Harmon, LCH Gallagher
US Patent 9,018,244, 2015
212015
Comparative Analysis of Spatial Patterns of Gene Expression in Drosophila melanogaster Imaginal Discs
CL Harmon, P Ahammad, A Hammonds, R Weiszmann, SE Celniker, ...
Annual International Conference on Research in Computational Molecular …, 2007
202007
Joint nonparametric alignment for analyzing spatial gene expression patterns in Drosophila imaginal discs
P Ahammad, CL Harmon, A Hammonds, SS Sastry, GM Rubin
2005 IEEE Computer Society Conference on Computer Vision and Pattern …, 2005
162005
Substituted triphenyl butenes
P Kushner, C Harmon, D Myles
US Patent 8,063,249, 2011
122011
Abstract P1-17-12: preliminary data from a phase I/II, multicenter, dose escalation study of OP-1250, an oral CERAN/SERD, in subjects with advanced and/or metastatic estrogen …
M Patel, C Alemany, Z Mitri, D Makower, V Borges, J Sparano, T Le, ...
Cancer Research 82 (4_Supplement), P1-17-12-P1-17-12, 2022
102022
OP-1250: A potent orally available complete antagonist of estrogen receptor-mediated signaling that shrinks wild type and mutant breast tumors
L Hodges-Gallagher, R Sun, D Myles, P Klein, JA Zujewski, C Harmon, ...
European Journal of Cancer 138, S55, 2020
62020
OP-1250 is a Complete Estrogen Receptor Antagonist (CERAN) that Lacks Agonist Activity on Cell Signaling and Proliferation in Breast Cancer Cells
L Hodges-Gallagher, R Sun, DC Myles, CL Harmon, PJ Kushner, ...
Apoptosis (GO. 0006915) 4, 6, 2020
52020
Anti-estrogenic compounds
PJ Kushner, DC Myles, CL Harmon, LCH GALLAGHER
US Patent App. 15/135,840, 2016
52016
Preliminary data from a phase 1/2, multicenter, dose escalation study of OP-1250, an oral CERAN/SERD, in patients with advanced and/or metastatic estrogen receptor (ER …
M Patel, C Alemany, Z Mitri, D Makower, V Borges, J Sparano, T Le, ...
Cancer Res 82 (4_Supplement), P1-17-12, 2022
42022
OP-1250, a complete estrogen receptor antagonist (CERAN) that shrinks estrogen receptor positive tumors and exhibits favorable pharmacokinetics
L Hodges-Gallagher, CL Harmon, R Sun, DC Myles, P Kushner
Cancer Research 80 (16_Supplement), 4376-4376, 2020
42020
Tetrahydro-1H-pyrido [3, 4-b] indole anti-estrogenic drugs
DC Myles, PJ Kushner, CL Harmon
US Patent 10,624,878, 2020
42020
Abstract P5-05-02: preclinical development of OP-1250, an oral complete estrogen receptor antagonist (CERAN) that shrinks ER-positive breast tumors in xenograft models
L Hodges-Gallagher, R Sun, DC Myles, CL Harmon, PJ Kushner
Cancer Research 80 (4_Supplement), P5-05-02-P5-05-02, 2020
32020
Tetrahydro-1H-pyrido [3, 4-b] indole anti-estrogenic drugs
DC Myles, PJ Kushner, CL Harmon
US Patent 10,292,971, 2019
32019
Abstract P2-24-07: Combination of complete estrogen receptor antagonist, OP-1250, and CDK4/6 inhibitors enhances tumor suppression and inhibition of cell cycle-related gene …
AD Parisian, GS Palanisamy, F Ortega, JL Sapugay, WJ Bodell, D Kulp, ...
Cancer Research 83 (5_Supplement), P2-24-07-P2-24-07, 2023
22023
Abstract LB122: the complete estrogen receptor antagonist (CERAN) OP-1250 shrinks ER+ brain metastases in an intracranial xenograft tumor model expressing mutant ESR1
L Hodges-Gallagher, AD Parisian, R Sun, DC Myles, PM Klein, ...
Cancer Research 81 (13_Supplement), LB122-LB122, 2021
22021
The system can't perform the operation now. Try again later.
Articles 1–20